Search results for "Anti tnf α therapy"

showing 1 items of 1 documents

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct